Fertility and Sterility
Volume 91, Issue 2 , Pages 456-488 , February 2009

The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report

  • Ricardo Azziz, M.D., M.P.H.

      Affiliations

    • Cedars-Sinai Medical Center and The David Geffen School of Medicine at UCLA, Los Angeles, California (Task Force Chair)
    • ,
  • Enrico Carmina, M.D.

      Affiliations

    • University of Palermo, Palermo, Italy
    • Corresponding Author InformationReprint requests: Enrico Carmina, M.D., Department of Clinical Medicine, University of Palermo, via delle Croci 47, 90139 Palermo, Italy (FAX: +39-091-655-5995).
    • ,
  • Didier Dewailly, M.D.

      Affiliations

    • Lille University Hospital, Lille, France
    • ,
  • Evanthia Diamanti-Kandarakis, M.D.

      Affiliations

    • University of Athens Medical School, Athens, Greece
    • ,
  • Héctor F. Escobar-Morreale, M.D., Ph.D.

      Affiliations

    • Hospital Ramon y Cajal, Madrid, Spain
    • ,
  • Walter Futterweit, M.D.

      Affiliations

    • Mount Sinai School of Medicine, New York, New York
    • ,
  • Onno E. Janssen, M.D.

      Affiliations

    • University of Essen, Essen, Germany
    • ,
  • Richard S. Legro, M.D.

      Affiliations

    • Pennsylvania State University School of Medicine, Hershey, Pennsylvania
    • ,
  • Robert J. Norman, M.D.

      Affiliations

    • University of Adelaide, Adelaide, Australia
    • ,
  • Ann E. Taylor

      Affiliations

    • Novartis, Cambridge, Massachusetts
    • ,
  • Selma F. Witchel, M.D.

      Affiliations

    • Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
    • ,
  • (Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society)

      Affiliations

    • Formerly the Androgen Excess Society.

Received 12 February 2008 ,Revised 19 June 2008 ,Accepted 23 June 2008.

References 

  1. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91:4237–4245
  2. Stein I, Leventhal M. Amenorrhea associated with bilaterl polycystic ovaries. Am J Obstet Gynecol. 1935;29:181–185
  3. Vallisneri A. Istoria della Generazione dell'Uomo, e degli Animali, se sia da' vermicelli spermatici, o dalle uova. Venezia: Appreso Gio Gabbriel Hertz, 1721.
  4. Chereau A. Mémoires pour servir à l'étude des maladies des ovaries. Paris: Fortin, Masson & Cie; 1844;
  5. Rokitanski C. A manual of pathological anatomy. Philadelphia, PA: Blanchard & Lea; 1855;
  6. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83:3078–3082
  7. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab. 1999;84:4006–4011
  8. Michelmore KF, Balen AH, Dunger DB, Vessey MP. Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol (Oxf). 1999;51:779–786
  9. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85:2434–2438
  10. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745–2749
  11. Raj SG, Thompson IE, Berger MJ, Talert LM, Taymor ML. Diagnostic value of androgen measurements in polycystic ovary syndrome. Obstet Gynecol. 1978;52:169–171
  12. Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed). 1986;293:355–359
  13. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In:  Dunaif A,  Givens JR,  Haseltine FP,  Merriam GR editor. Polycystic ovary syndrome. Boston, MA: Blackwell Scientific Publications; 1992;p. 377–384
  14. ESHRE/ASRM . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25
  15. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–47
  16. Broekmans FJ, Knauff EAH, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BCJM. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG. 2006;113:1210–1217
  17. Lewis T. Reflections upon reform in medical education. Lancet. 1944;243:619–621
  18. White KP, Harth M. Classification, epidemiology, and natural history of fibromyalgia. Curr Pain Headache Rep. 2001;5:320–329
  19. Aaron LA, Buchwald D. A review of the evidence for overlap among unexplained clinical conditions. Ann Intern Med. 2001;134:868–881
  20. Linder R, Dinser R, Wagner M, Krueger GR, Hoffmann A. Generation of classification criteria for chronic fatigue syndrome using an artificial neural network and traditional criteria set. In Vivo. 2002;16:37–43
  21. Corazziari E. Definition and epidemiology of functional gastrointestinal disorders. Best Pract Res Clin Gastroenterol. 2004;18:613–631
  22. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725
  23. Smith EL, Shmerling RH. The American College of Rheumatology criteria for the classification of systemic lupus erythematosus: strengths, weaknesses, and opportunities for improvement. Lupus. 1999;8:586–595
  24. Wiedermann FJ, Mayr A, Schobersberger W, Mutz N. Definition and classification of the antiphospholipid syndrome. J Cardiovasc Surg (Torino). 1999;40:919–920
  25. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care. 2003;26:575–581
  26. Marchesini G, Forlani G, Cerrelli F, Manini R, Natale S, Baraldi L, et al. WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with Type 2 diabetes. Diabet Med. 2004;21:383–387
  27. Feng Q, Zhou ZG, Tang WL, Yang XL, Long X. [Comparison of 3 working definitions of metabolic syndrome in male medical examinees]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2005;30:130–134
  28. Agency for Healthcare Research and Quality . Defining and Managing Chronic Fatigue Syndrome. Summary, Evidence Report/Technology Assessment. 2001;http://www.ahrq.gov/clinic/cfssum.htm
  29. Crichton M. The Caltech Michelin Lecture: Aliens Cause Global Warming. Available at: http://www.crichton-official.com/speeches/speeches_quote04.html. 2003.
  30. NIH Consensus Development Program. Frequently Asked Questions: What is an NIH Consensus Statement? (http://consensus.nih.gov/about/faq.htm). 2005.
  31. Legro RS, Kunselman AR, Demers L, Wang SC, Bentley-Lewis R, Dunaif A. Elevated dehydroepiandrosterone sulfate levels as the reproductive phenotype in the brothers of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87:2134–2138
  32. Legro RS, Driscoll D, Strauss JF, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA. 1998;95:14956–14960
  33. Yildiz BO, Yarali H, Oguz H, Bayraktar M. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:2031–2036
  34. Norman RJ, Masters S, Hague W. Hyperinsulinemia is common in family members of women with polycystic ovary syndrome. Fertil Steril. 1996;66:942–947
  35. Kashar-Miller M, Azziz R. Heritability and the risk of developing androgen excess. J Steroid Biochem Mol Biol. 1999;69:261–268
  36. Kahsar-Miller MD, Nixon C, Boots LR, Go RC, Azziz R. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril. 2001;75:53–58
  37. Sanders EB, Aston CE, Ferrell RE, Witchel SF. Inter- and intrafamilial variability in premature pubarche and polycystic ovary syndrome. Fertil Steril. 2002;78:473–478
  38. Memisoglu A, Hu FB, Hankinson SE, Manson JE, De Vivo I, Willett WC, et al. Interaction between a peroxisome proliferator-activated receptor gamma gene polymorphism and dietary fat intake in relation to body mass. Hum Mol Genet. 2003;12:2923–2929
  39. Brant SR, Shugart YY. Inflammatory bowel disease gene hunting by linkage analysis: rationale, methodology, and present status of the field. Inflamm Bowel Dis. 2004;10:300–311
  40. Ahmad T, Marshall S, Jewell D. Genotype-based phenotyping heralds a new taxonomy for inflammatory bowel disease. Curr Opin Gastroenterol. 2003;19:327–335
  41. Hugot JP, Laurent-Puig P, Gower-Rousseau C, Olson JM, Lee JC, Beaugerie L, et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature. 1996;379:821–823
  42. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411:599–603
  43. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411:603–606
  44. Lesage S, Zouali H, Cezard JP, Colombel JF, Belaiche J, Almer S, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet. 2002;70:845–857
  45. Ahmad T, Armuzzi A, Bunce M, Mulcahy-Hawes K, Marshall SE, Orchard TR, et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology. 2002;122:854–866
  46. Carmina E, Rosato F, Janni A, Rizzo M, Longo RA. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab. 2006;91:2–6
  47. Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004;89:453–462
  48. Souter I, Sanchez LA, Perez M, Bartolucci AA, Azziz R. The prevalence of androgen excess among patients with minimal unwanted hair growth. Am J Obstet Gynecol. 2004;191:1914–1920
  49. Vexiau P, Husson C, Chivot M, Brerault JL, Fiet J, Julien R, et al. Androgen excess in women with acne alone compared with women with acne and/or hirsutism. J Invest Dermatol. 1990;94:279–283
  50. Timpatanapong P, Rojanasakul A. Hormonal profiles and prevalence of polycystic ovary syndrome in women with acne. J Dermatol. 1997;24:223–229
  51. Borgia F, Cannavo S, Guarneri F, Cannavo SP, Vaccaro M, Guarneri B. Correlation between endocrinological parameters and acne severity in adult women. Acta Derm Venereol. 2004;84:201–204
  52. Cela E, Robertson C, Rush K, Kousta E, White DM, Wilson H, et al. Prevalence of polycystic ovaries in women with androgenic alopecia. Eur J Endocrinol. 2003;149:439–442
  53. Futterweit W, Dunaif A, Yeh HC, Kingsley P. The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. J Am Acad Dermatol. 1988;19:831–836
  54. Vexiau P, Chaspoux C, Boudou P, Fiet J, Abramovici Y, Rueda MJ, et al. Role of androgens in female-pattern androgenetic alopecia, either alone or associated with other symptoms of hyperandrogenism. Arch Dermatol Res. 2000;292:598–604
  55. Chiazze L, Brayer FT, Macisco JJ, Parker MP, Duffy BJ. The length and variability of the human menstrual cycle. JAMA. 1968;203:377–380
  56. Treloar AE, Boynton RE, Behn BG, Brown BW. Variation of the human menstrual cycle through reproductive life. Int J Fertil. 1967;12:77–126
  57. Solomon CG, Hu FB, Dunaif A, Rich-Edwards J, Willett WC, Hunter DJ, et al. Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. JAMA. 2001;286:2421–2426
  58. Polson DW, Adams J, Wadsworth J, Franks S. Polycystic ovaries—a common finding in normal women. Lancet. 1988;1:870–872
  59. Clayton RN, Ogden V, Hodgkinson J, Worswick L, Rodin DA, Dyer S, et al. How common are polycystic ovaries in normal women and what is their significance for the fertility of the population?. Clin Endocrinol (Oxf). 1992;37:127–134
  60. Koivunen R, Laatikainen T, Tomas C, Huhtaniemi I, Tapanainen J, Martikainen H. The prevalence of polycystic ovaries in healthy women. Acta Obstet Gynecol Scand. 1999;78:137–141
  61. Farquhar CM, Birdsall M, Manning P, Mitchell JM, France JT. The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women. Aust N Z J Obstet Gynaecol. 1994;34:67–72
  62. Lowe P, Kovacs G, Howlett D. Incidence of polycystic ovaries and polycystic ovary syndrome amongst women in Melbourne, Australia. Aust N Z J Obstet Gynaecol. 2005;45:17–19
  63. Farquhar CM, Birdsall M, Manning P, Mitchell JM. Transabdominal versus transvaginal ultrasound in the diagnosis of polycystic ovaries in a population of randomly selected women. Ultrasound Obstet Gynecol. 1994;4:54–59
  64. Futterweit W, Yeh HC, Mechanick JI. Ultrasonographic study of ovaries of 19 women with weight loss-related hypothalamic oligo-amenorrhea. Biomed Pharmacother. 1988;42:279–283
  65. Ardaens Y, Robert Y, Lemaitre L, Fossati P, Dewailly D. Polycystic ovarian disease: contribution of vaginal endosonography and reassessment of ultrasonic diagnosis. Fertil Steril. 1991;55:1062–1068
  66. Hassan MA, Killick SR. Ultrasound diagnosis of polycystic ovaries in women who have no symptoms of polycystic ovary syndrome is not associated with subfecundity or subfertility. Fertil Steril. 2003;80:966–975
  67. Wong IL, Morris RS, Lobo RA, Paulson RJ, Sauer MV. Isolated polycystic morphology in ovum donors predicts response to ovarian stimulation. Hum Reprod. 1995;10:524–528
  68. Adams JM, Taylor AE, Crowley WF, Hall JE. Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome. J Clin Endocrinol Metab. 2004;89:4343–4350
  69. Joseph-Horne R, Mason H, Batty S, White D, Hillier S, Urquhart M, et al. Luteal phase progesterone excretion in ovulatory women with polycystic ovaries. Hum Reprod. 2002;17:1459–1463
  70. Norman RJ, Hague WM, Masters SC, Wang XJ. Subjects with polycystic ovaries without hyperandrogenaemia exhibit similar disturbances in insulin and lipid profiles as those with polycystic ovary syndrome. Hum Reprod. 1995;10:2258–2261
  71. Carmina E, Wong L, Chang L, Paulson RJ, Sauer MV, Stanczyk FZ, et al. Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound. Hum Reprod. 1997;12:905–909
  72. Chang PL, Lindheim SR, Lowre C, Ferin M, Gonzalez F, Berglund L, et al. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary–ovarian responses to gonadotropin-releasing hormone-agonist testing. J Clin Endocrinol Metab. 2000;85:995–1000
  73. Kousta E, Cela E, Lawrence N, Penny A, Millauer B, White D, et al. The prevalence of polycystic ovaries in women with a history of gestational diabetes. Clin Endocrinol (Oxf). 2000;53:501–507
  74. Rodin DA, Bano G, Bland JM, Taylor K, Nussey SS. Polycystic ovaries and associated metabolic abnormalities in Indian subcontinent Asian women. Clin Endocrinol (Oxf). 1998;49:91–99
  75. NCEP . Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421
  76. Gennarelli G, Holte J, Berglund L, Berne C, Massobrio M, Lithell H. Prediction models for insulin resistance in the polycystic ovary syndrome. Hum Reprod. 2000;15:2098–2102
  77. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356–359
  78. Korhonen S, Hippelainen M, Niskanen L, Vanhala M, Saarikoski S. Relationship of the metabolic syndrome and obesity to polycystic ovary syndrome: a controlled, population-based study. Am J Obstet Gynecol. 2001;184:289–296
  79. Conn JJ, Jacobs HS, Conway GS. The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. Clin Endocrinol (Oxf). 2000;52:81–86
  80. Peppard HR, Marfori J, Iuorno MJ, Nestler JE. Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes. Diabetes Care. 2001;24:1050–1052
  81. Escobar-Morreale HF, Roldan B, Barrio R, Alonso M, Sancho J, de la Calle H, et al. High prevalence of the polycystic ovary syndrome and hirsutism in women with type 1 diabetes mellitus. J Clin Endocrinol Metab. 2000;85:4182–4187
  82. Roldan B, Escobar-Morreale HF, Barrio R, de La Calle H, Alonso M, Garcia-Robles R, et al. Identification of the source of androgen excess in hyperandrogenic type 1 diabetic patients. Diabetes Care. 2001;24:1297–1299
  83. Ferriman D, Purdie AW. The aetiology of oligomenorrhoea and/or hirsuties: a study of 467 patients. Postgrad Med J. 1983;59:17–20
  84. Conway GS, Honour JW, Jacobs HS. Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. Clin Endocrinol (Oxf). 1989;30:459–470
  85. Kiddy DS, Sharp PS, White DM, Scanlon MF, Mason HD, Bray CS, et al. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol. 1990;32:213–220
  86. Rajkhowa M, Talbot JA, Jones PW, Pettersson K, Haavisto AM, Huhtaniemi I, et al. Prevalence of an immunological LH beta-subunit variant in a UK population of healthy women and women with polycystic ovary syndrome. Clin Endocrinol. 1995;43:297–303
  87. Balen AH, Conway GS, Kaltsas G, Techatrasak K, Manning PJ, West C, et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod. 1995;10:2107–2111
  88. Falsetti L, Eleftheriou G. Hyperinsulinemia in the polycystic ovary syndrome: a clinical, endocrine and echographic study in 240 patients. Gynecol Endocrinol. 1996;10:319–326
  89. Khoury MY, Baracat EC, Pardini DP, Haidar MA, da Motta EL, de Lima GR. Polycystic ovary syndrome: clinical and laboratory evaluation. Sao Paulo Med J. 1996;114:1222–1225
  90. Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscl Thromb Vasc Biol. 1995;15:821–826
  91. Carmina E. Prevalence of idiopathic hirsutism. Eur J Endocrinol. 1998;139:421–423
  92. Alborzi S, Khodaee R, Parsanejad ME. Ovarian size and response to laparoscopic ovarian electro-cauterization in polycystic ovarian disease. Int J Gynaecol Obstet. 2001;74:269–274
  93. Williamson K, Gunn AJ, Johnson N, Milsom SR. The impact of ethnicity on the presentation of polycystic ovarian syndrome. Aust N Z J Obstet Gynaecol. 2001;41:202–206
  94. Haddad L, Evans JC, Gharani N, Robertson C, Rush K, Wiltshire S, et al. Variation within the type 2 diabetes susceptibility gene calpain-10 and polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87:2606–2610
  95. Amer SAKS, Li TC, Bygrave C, Sprigg A, Saravelos H, Cooke ID. An evaluation of the inter-observer and intra-observer variability of the ultrasound diagnosis of polycystic ovaries. Hum Reprod. 2002;17:1616–1622
  96. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metab Clin Exp. 2003;52:908–915
  97. Orio F, Matarese G, Di Biase S, Palomba S, Labella D, Sanna V, et al. Exon 6 and 2 peroxisome proliferator-activated receptor-gamma polymorphisms in polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:5887–5892
  98. Chang WY, Knochenhauer ES, Bartolucci AA, Azziz R. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril. 2005;83:1717–1723
  99. Hahn S, Tan S, Elsenbruch S, Quadbeck B, Herrmann BL, Mann K, et al. Clinical and biochemical characterization of women with polycystic ovary syndrome in North Rhine-Westphalia. Horm Metab Res. 2005;37:438–444
  100. Diamanti-Kandarakis E, Panidis D. Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS. Clin Endocrinol. 2007;67:735–742
  101. Farah L, Lazenby AJ, Boots LR, Azziz R. Prevalence of polycystic ovary syndrome in women seeking treatment from community electrologists. Alabama Professional Electrology Association Study Group. J Reprod Med. 1999;44:870–874
  102. Elting MW, Korsen TJ, Rekers-Mombarg LT, Schoemaker J. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum Reprod. 2000;15:24–28
  103. Winters SJ, Talbott E, Guzick DS, Zborowski J, McHugh KP. Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome. Fertil Steril. 2000;73:724–729
  104. Malcolm CE, Cumming DC. Does anovulation exist in eumenorrheic women?. Obstet Gynecol. 2003;102:317–318
  105. Petsos P, Mamtora H, Ratcliffe WA, Anderson DC. Inadequate luteal phase usually indicates ovulatory dysfunction: observations from serial hormone and ultrasound monitoring of 115 cycles. Gynecol Endocrinol. 1987;1:37–45
  106. Page LA, Beauregard LJ, Bode HH, Beitins IZ. Hypothalamic–pituitary–ovarian function in menstruating women with Turner syndrome (45,X). Pediatr Res. 1990;28:514–517
  107. Azziz R, Waggoner WT, Ochoa T, Knochenhauer ES, Boots LR. Idiopathic hirsutism: an uncommon cause of hirsutism in Alabama. Fertil Steril. 1998;70:274–278
  108. Carmina E, Lobo RA. Do hyperandrogenic women with normal menses have polycystic ovary syndrome?. Fertil Steril. 1999;71:319–322
  109. Norman RJ, Masters SC, Hague W, Beng C, Pannall P, Wang JX. Metabolic approaches to the subclassification of polycystic ovary syndrome. Fertil Steril. 1995;63:329–335
  110. Legro RS, Myers ER, Barnhart HX, Carson SA, Diamond MP, Carr BR, et al. The Pregnancy in Polycystic Ovary Syndrome study: baseline characteristics of the randomized cohort including racial effects. Fertil Steril. 2006;86:914–933
  111. Miller KK, Rosner W, Lee H, Hier J, Sesmilo G, Schoenfeld D, et al. Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. J Clin Endocrinol Metab. 2004;89:525–533
  112. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666–3672
  113. Van Uytfanghe K, Stockl D, Kaufman JM, Fiers T, De Leenheer A, Thienpont LM. Validation of 5 routine assays for serum free testosterone with a candidate reference measurement procedure based on ultrafiltration and isotope dilution-gas chromatography-mass spectrometry. Clin Biochem. 2005;38:253–261
  114. Van Uytfanghe K, Stockl D, Kaufman JM, Fiers T, Ross HA, De Leenheer AP, et al. Evaluation of a candidate reference measurement procedure for serum free testosterone based on ultrafiltration and isotope dilution-gas chromatography-mass spectrometry. Clin Chem. 2004;50:2101–2110
  115. Boots LR, Potter S, Potter D, Azziz R. Measurement of total serum testosterone levels using commercially available kits: high degree of between-kit variability. Fertil Steril. 1998;69:286–292
  116. Fitzgerald RL, Herold DA. Serum total testosterone: immunoassay compared with negative chemical ionization gas chromatography-mass spectrometry. Clin Chem. 1996;42:749–755
  117. Taieb J, Mathian B, Millot F, Patricot MC, Mathieu E, Queyrel N, et al. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem. 2003;49:1381–1395
  118. Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab. 2004;89:534–543
  119. Pugeat M, Crave JC, Tourniaire J, Forest MG. Clinical utility of sex hormone-binding globulin measurement. Horm Res. 1996;45:148–155
  120. Escobar-Morreale HF, Asuncion M, Calvo RM, Sancho J, San Millan JL. Receiver operating characteristic analysis of the performance of basal serum hormone profiles for the diagnosis of polycystic ovary syndrome in epidemiological studies. Eur J Endocrinol. 2001;145:619–624
  121. Azziz R, Black V, Hines GA, Fox LM, Boots LR. Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic–pituitary–adrenal axis. J Clin Endocrinol Metab. 1998;83:2317–2323
  122. Azziz R, Fox LM, Zacur HA, Parker CR, Boots LR. Adrenocortical secretion of dehydroepiandrosterone in healthy women: highly variable response to adrenocorticotropin. J Clin Endocrinol Metab. 2001;86:2513–2517
  123. Lobo RA, Paul WL, Goebelsmann U. Dehydroepiandrosterone sulfate as an indicator of adrenal androgen function. Obstet Gynecol. 1981;57:69–73
  124. Korth-Schutz S, Levine LS, New MI. Dehydroepiandrosterone sulfate (DS) levels, a rapid test for abnormal adrenal androgen secretion. J Clin Endocrinol Metab. 1976;42:1005–1013
  125. Feher T, Poteczin E, Bodrogi L. Relationship between serum dehydroepiandrosterone sulphate and urinary 17-ketosteroid values. Exp Clin Endocrinol. 1985;85:209–216
  126. Abraham GE, Chakmakjian ZH. Serum steroid levels during the menstrual cycle in a bilaterally adrenalectomized woman. J Clin Endocrinol Metab. 1973;37:581–587
  127. Abraham GE. Ovarian and adrenal contribution to peripheral androgens during the menstrual cycle. J Clin Endocrinol Metab. 1974;39:340–346
  128. Vermeulen A. Androgen secretion by adrenals and gonads. In:  Mahesh MB,  Greenblatt RM editor. Hirsutism and virilism. Boston: John Wright/PSG Inc.; 1983;p. 17
  129. Nieschlag E, Loriaux DL, Ruder HJ, Zucker IR, Kirschner MA, Lipsett MB. The secretion of dehydroepiandrosterone and dehydroepiandrosterone sulphate in man. J Endocrinol. 1973;57:123–134
  130. Mikulecky M, Kreze A, Putz Z, Moravcik M. Daily variation of serum cortisol, 17-hydroxyprogesterone and five androgens in healthy women. Braz J Med Biol Res. 1995;28:485–490
  131. Rosenfeld RS, Rosenberg BJ, Fukushima DK, Hellman L. 24-Hour secretory pattern of dehydroisoandrosterone and dehydroisoandrosterone sulfate. J Clin Endocrinol Metab. 1975;40:850–855
  132. Wang DY, Bulbrook RD, Sneddon A, Hamilton T. The metabolic clearance rates of dehydroepiandrosterone, testosterone and their sulphate esters in man, rat and rabbit. J Endocrinol. 1967;38:307–318
  133. Gant NF, Hutchinson HT, Siiteri PK, MacDonald PC. Study of the metabolic clearance rate of dehydroisoandrosterone sulfate in pregnancy. Am J Obstet Gynecol. 1971;111:555–563
  134. Baulieu EE, Corpechot C, Dray F, Emiliozzi R, Lebeau MC, Mauvais Jarvis P, et al. An adrenal-secreted “androgen”: dehydroisoandrosterone sulfate. Its metabolism and a tentative generalization on the metabolism of other steroid conjugates in man. Recent Prog Horm Res. 1965;21:411–500
  135. Longcope C. Dehydroepiandrosterone metabolism. J Endocrinol. 1996;150(Suppl):S125–S127
  136. Legrain S, Massien C, Lahlou N, Roger M, Debuire B, Diquet B, et al. Dehydroepiandrosterone replacement administration: pharmacokinetic and pharmacodynamic studies in healthy elderly subjects. J Clin Endocrinol Metab. 2000;85:3208–3217
  137. Carmina E, Rosato F, Janni A. Increased DHEAs levels in PCO syndrome: evidence for the existence of two subgroups of patients. J Endocrinol Invest. 1986;9:5–9
  138. Wild RA, Umstot ES, Andersen RN, Ranney GB, Givens JR. Androgen parameters and their correlation with body weight in one hundred thirty-eight women thought to have hyperandrogenism. Am J Obstet Gynecol. 1983;146:602–606
  139. Kumar A, Woods KS, Bartolucci AA, Azziz R. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). 2005;62:644–649
  140. Hammer F, Subtil S, Lux P, Maser-Gluth C, Stewart PM, Allolio B, et al. No evidence for hepatic conversion of dehydroepiandrosterone (DHEA) sulfate to DHEA: in vivo and in vitro studies. J Clin Endocrinol Metab. 2005;90:3600–3605
  141. Huerta R, Dewailly D, Decanter C, Knochenhauer ES, Boots LR, Azziz R. 11beta-hydroxyandrostenedione and delta5-androstenediol as markers of adrenal androgen production in patients with 21-hydroxylase-deficient nonclassic adrenal hyperplasia. Fertil Steril. 1999;72:996–1000
  142. Lobo RA, Goebelsmann U. Evidence for reduced 3 beta-ol-hydroxysteroid dehydrogenase activity in some hirsute women thought to have polycystic ovary syndrome. J Clin Endocrinol Metab. 1981;53:394–400
  143. Zerah M, Rheaume E, Mani P, Schram P, Simard J, Labrie F, et al. No evidence of mutations in the genes for type I and type II 3 beta-hydroxysteroid dehydrogenase (3 beta HSD) in nonclassical 3 beta HSD deficiency. J Clin Endocrinol Metab. 1994;79:1811–1817
  144. Carbunaru G, Prasad P, Scoccia B, Shea P, Hopwood N, Ziai F, et al. The hormonal phenotype of Nonclassic 3 beta-hydroxysteroid dehydrogenase (HSD3B) deficiency in hyperandrogenic females is associated with insulin-resistant polycystic ovary syndrome and is not a variant of inherited HSD3B2 deficiency. J Clin Endocrinol Metab. 2004;89:783–794
  145. Garn SM. Types and distribution of the hair in man. Ann N Y Acad Sci. 1951;53:498–507
  146. Moncada E. Familial study of hirsutism. J Clin Endocrinol Metab. 1970;31:556–564
  147. Lunde O, Grottum P. Body hair growth in women: normal or hirsute. Am J Phys Anthropol. 1984;64:307–313
  148. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440–1447
  149. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol. 1981;140:815–830
  150. DeUgarte CM, Woods KS, Bartolucci AA, Azziz R. Degree of facial and body terminal hair growth in unselected black and white women: toward a populational definition of hirsutism. J Clin Endocrinol Metab. 2006;91:1345–1350
  151. Carmina E, Koyama T, Chang L, Stanczyk FZ, Lobo RA. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?. Am J Obstet Gynecol. 1992;167:1807–1812
  152. Wijeyaratne CN, Balen AH, Barth JH, Belchetz PE. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference?. Clin Endocrinol (Oxf). 2002;57:343–350
  153. Falsetti L, Gambera A, Andrico S, Sartori E. Acne and hirsutism in polycystic ovary syndrome: clinical, endocrine–metabolic and ultrasonographic differences. Gynecol Endocrinol. 2002;16:275–284
  154. Rea JN, Newhouse ML, Halil T. Skin disease in Lambeth. A community study of prevalence and use of medical care. Br J Prev Soc Med. 1976;30:107–114
  155. Johnson MT, Roberts J. Skin conditions and related need for medical care among persons 1–74 years. United States, 1971–1974. Vital Health Stat. 1978;11:i–v1–72
  156. Cunliffe WJ, Gould DJ. Prevalence of facial acne vulgaris in late adolescence and in adults. Br Med J. 1979;1:1109–1110
  157. Dalgard F, Svensson A, Holm JO, Sundby J. Self-reported skin morbidity in Oslo. Associations with sociodemographic factors among adults in a cross-sectional study. Br J Dermatol. 2004;151:452–457
  158. Galobardes B, Davey Smith G, Jefferys M, McCarron P. Has acne increased? Prevalence of acne history among university students between 1948 and 1968. The Glasgow Alumni Cohort Study. Br J Dermatol. 2005;152:824–825
  159. Rosenfield RL. Polycystic ovary syndrome and insulin-resistant hyperinsulinemia. J Am Acad Dermatol. 2001;45:S95–S104
  160. Deplewski D, Rosenfield RL. Role of hormones in pilosebaceous unit development. Endocr Rev. 2000;21:363–392
  161. Schweikert HU, Wilson JD. Regulation of human hair growth by steroid hormones. I. Testerone metabolism in isolated hairs. J Clin Endocrinol Metab. 1974;38:811–819
  162. O'Driscoll JB, Mamtora H, Higginson J, Pollock A, Kane J, Anderson DC. A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients presenting with hirsutism or androgenic alopecia. Clin Endocrinol (Oxf). 1994;41:231–236
  163. Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol. 1977;97
  164. Franks S. Polycystic ovary syndrome: a changing perspective. Clin Endocrinol (Oxf). 1989;31:87–120
  165. Carmina E, Lobo RA. Polycystic ovaries in hirsute women with normal menses. Am J Med. 2001;111:602–606
  166. Ehrmann DA, Rosenfield RL, Barnes RB, Brigell DF, Sheikh Z. Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med. 1992;327:157–162
  167. Pache TD, Wladimiroff JW, Hop WC, Fauser BC. How to discriminate between normal and polycystic ovaries: transvaginal US study. Radiology. 1992;183:421–423
  168. van Santbrink EJ, Hop WC, Fauser BC. Classification of normogonadotropic infertility: polycystic ovaries diagnosed by ultrasound versus endocrine characteristics of polycystic ovary syndrome. Fertil Steril. 1997;67:452–458
  169. Jonard S, Robert Y, Cortet-Rudelli C, Pigny P, Decanter C, Dewailly D. Ultrasound examination of polycystic ovaries: is it worth counting the follicles?. Hum Reprod. 2003;18:598–603
  170. Dewailly D. Definition and significance of polycystic ovaries. Baillieres Clin Obstet Gynaecol. 1997;11:349–368
  171. Carmina E, Orio F, Palomba S, Longo RA, Lombardi G, Lobo RA. Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters. Fertil Steril. 2005;84:413–419
  172. Christensen JT, Boldsen J, Westergaard JG. Ovarian volume in gynecologically healthy women using no contraception, or using IUD or oral contraception. Acta Obstet Gynecol Scand. 1997;76:784–789
  173. Buckett WM, Bouzayen R, Watkin KL, Tulandi T, Tan SL. Ovarian stromal echogenicity in women with normal and polycystic ovaries. Hum Reprod. 1999;14:618–621
  174. Dewailly D, Robert Y, Helin I, Ardaens Y, Thomas-Desrousseaux P, Lemaitre L, et al. Ovarian stromal hypertrophy in hyperandrogenic women. Clin Endocrinol (Oxf). 1994;41:557–562
  175. Laven JS, Imani B, Eijkemans MJ, de Jong FH, Fauser BC. Absent biologically relevant associations between serum inhibin B concentrations and characteristics of polycystic ovary syndrome in normogonadotrophic anovulatory infertility. Hum Reprod. 2001;16:1359–1364
  176. Jonard S, Robert Y, Cortet-Rudelli C, Pigny P, Decanter C, Dewailly D. Ultrasound examination of polycystic ovaries: is it worth counting the follicles?. Hum Reprod. 2003;18:598–603
  177. Taylor AE, McCourt B, Martin KA, Anderson EJ, Adams JM, Schoenfeld D, et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82:2248–2256
  178. Morales AJ, Laughlin GA, Butzow T, Maheshwari H, Baumann G, Yen SS. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab. 1996;81:2854–2864
  179. Arroyo A, Laughlin GA, Morales AJ, Yen SS. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity. J Clin Endocrinol Metab. 1997;82:3728–3733
  180. Homburg R. What is polycystic ovarian syndrome? A proposal for a consensus on the definition and diagnosis of polycystic ovarian syndrome. Hum Reprod. 2002;17:2495–2499
  181. Manieri C, Pastorino R, Marolda AR, Musso MC, Gellona A, Barberis A, et al. Gonadotropin evaluation in the diagnosis of polycystic ovary syndrome using either a monoclonal or a polyclonal antibody radioimmunoassay. J Endocrinol Invest. 1992;15:219–222
  182. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38:1165–1174
  183. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998;83:2694–2698
  184. DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2005;83:1454–1460
  185. Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW, Ryan KJ. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab. 1986;62:904–910
  186. Nestler JE, Jakubowicz DJ, de Vargas AF, Brik C, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab. 1998;83:2001–2005
  187. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1991;72:83–89
  188. Plymate SR, Matej LA, Jones RE, Friedl KE. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab. 1988;67:460–464
  189. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84:165–169
  190. Dunaif A, Finegood DT. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1996;81:942–947
  191. Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest. 1995;96:520–527
  192. Ehrmann DA, Breda E, Corcoran MC, Cavaghan MK, Imperial J, Toffolo G, et al. Impaired beta-cell compensation to dexamethasone-induced hyperglycemia in women with polycystic ovary syndrome. Am J Physiol Endocrinol Metab. 2004;287:E241–E246
  193. Ehrmann DA, Kasza K, Azziz R, Legro RS, Ghazzi MN. Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:66–71
  194. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27:1487–1495
  195. Quon MJ. Limitations of the fasting glucose to insulin ratio as an index of insulin sensitivity. J Clin Endocrinol Metab. 2001;86:4615–4617
  196. Carmina E, Lobo RA. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril. 2004;82:661–665
  197. Yang YJ, Youn JH, Bergman RN. Modified protocols improve insulin sensitivity estimation using the minimal model. Am J Physiol. 1987;253:E595–E602
  198. Ferrannini E, Mari A. How to measure insulin sensitivity. J Hypertens. 1998;16:895–906
  199. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462–1470
  200. Breda E, Cavaghan MK, Toffolo G, Polonsky KS, Cobelli C. Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity. Diabetes. 2001;50:150–158
  201. Robbins DC, Andersen L, Bowsher R, Chance R, Dinesen B, Frank B, et al. Report of the American Diabetes Association's Task Force on standardization of the insulin assay. Diabetes. 1996;45:242–256
  202. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:1929–1935
  203. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22:141–146
  204. Carmina E, Chu MC, Longo RA, Rini GB, Lobo RA. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab. 2005;90:2545–2549
  205. Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv. 2004;59:141–154
  206. Dunaif A, Sorbara L, Delson R, Green G. Ethnicity and polycystic ovary syndrome are associated with independent and additive decreases in insulin action in Caribbean-Hispanic women. Diabetes. 1993;42:1462–1468
  207. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. 2001;111:607–613
  208. Graf MJ, Richards CJ, Brown V, Meissner L, Dunaif A. The independent effects of hyperandrogenaemia, hyperinsulinaemia, and obesity on lipid and lipoprotein profiles in women. Clin Endocrinol. 1990;33:119–131
  209. Talbott E, Clerici A, Berga SL, Kuller L, Guzick D, Detre K, et al. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case–control study. J Clin Epidemiol. 1998;51:415–422
  210. Legro RS, Azziz R, Ehrmann D, Fereshetian AG, O'Keefe M, Ghazzi MN. Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. J Clin Endocrinol Metab. 2003;88:5137–5144
  211. Valkenburg O, Steegers-Theunissen RPM, Smedts HPM, Dallinga-Thie GM, Fauser BCJM, Westerveld EH, et al. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case–control study. J Clin Endocrinol Metab. 2008;93:470–476
  212. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607
  213. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1985;61:946–951
  214. Robinson S, Henderson AD, Gelding SV. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol. 1996;44:277–284
  215. Recabarren SE, Smith R, Rios R. Metabolic profile in sons of women with polycystic ovary syndrome (PCOS). J Clin Endocriinol Metab. 2008;93:1820–1826
  216. Sam S, Legro RS, Essah PA, Apridonidze T, Dunaif A. Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome. Proc Natl Acad Sci USA. 2006;103:7030–7035
  217. Sam S, Legro RS, Bentley-Lewis R, Dunaif A. Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:4797–4802
  218. Taponen S, Martikainen H, Jarvelin MR, Sovio U, Laitinen J, Pouta A, et al. Metabolic cardiovascular disease risk factors in women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study. J Clin Endocrinol Metab. 2004;89:2114–2118
  219. Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001;86:1626–1632
  220. Alvarez-Blasco F, Botella-Carretero JI, San Millan JL, Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med. 2006;166:2081–2086
  221. Yildiz BO, Knochenhauer ES, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93:162–168
  222. Carmina E, Legro RS, Stamets K, Lowell J, Lobo RA. Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Hum Reprod. 2003;18:2289–2293
  223. Laitinen J, Taponen S, Martikainen H, Pouta A, Millwood I, Hartikainen AL, et al. Body size from birth to adulthood as a predictor of self-reported polycystic ovary syndrome symptoms. Int J Obes Relat Metab Disord. 2003;27:710–715
  224. Legro RS, Bentley-Lewis R, Driscoll D, Wang SC, Dunaif A. Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity. J Clin Endocrinol Metab. 2002;87:2128–2133
  225. Bulun SE, Noble LS, Takayama K, Michael MD, Agarwal V, Fisher C, et al. Endocrine disorders associated with inappropriately high aromatase expression. J Steroid Biochem Mol Biol. 1997;61:133–139
  226. Moran C, Tapia MC, Hernandez E, Vazquez G, Garcia-Hernandez E, Bermudez JA. Etiological review of hirsutism in 250 patients. Arch Med Res. 1994;25:311–314
  227. Luciano AA, Chapler FK, Sherman BM. Hyperprolactinemia in polycystic ovary syndrome. Fertil Steril. 1984;41:719–725
  228. Romaguera J, Moran C, Diaz-Montes TP, Hines GA, Cruz RI, Azziz R. Prevalence of 21-hydroxylase-deficient nonclassic adrenal hyperplasia and insulin resistance among hirsute women from Puerto Rico. Fertil Steril. 2000;74:59–62
  229. Escobar-Morreale HF. Macroprolactinemia in women presenting with hyperandrogenic symptoms: implications for the management of polycystic ovary syndrome. Fertil Steril. 2004;82:1697–1699
  230. Janssen OE, Mehlmauer N, Hahn S, Offner AH, Gartner R. High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Eur J Endocrinol. 2004;150:363–369
  231. Glintborg D, Henriksen JE, Andersen M, Hagen C, Hangaard J, Rasmussen PE, et al. Prevalence of endocrine diseases and abnormal glucose tolerance tests in 340 Caucasian premenopausal women with hirsutism as the referral diagnosis. Fertil Steril. 2004;82:1570–1579
  232. Redmond GP. Thyroid dysfunction and women's reproductive health. Thyroid. 2004;14(Suppl 1):S5–S15
  233. Lazarus JH. Thyroid disorders associated with pregnancy: etiology, diagnosis, and management. Treat Endocrinol. 2005;4:31–41
  234. Pop VJ, Brouwers EP, Vader HL, Vulsma T, van Baar AL, de Vijlder JJ. Maternal hypothyroxinaemia during early pregnancy and subsequent child development: a 3-year follow-up study. Clin Endocrinol (Oxf). 2003;59:282–288
  235. Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J, et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med. 1999;341:549–555
  236. Krassas GE, Pontikides N, Kaltsas T, Papadopoulou P, Batrinos M. Menstrual disturbances in thyrotoxicosis. Clin Endocrinol (Oxf). 1994;40:641–644
  237. Krassas GE, Pontikides N, Kaltsas T, Papadopoulou P, Paunkovic J, Paunkovic N, et al. Disturbances of menstruation in hypothyroidism. Clin Endocrinol (Oxf). 1999;50:655–659
  238. Christensen SB, Ericsson UB, Janzon L, Tibblin S, Trell E. The prevalence of thyroid disorders in a middle-aged female population, with special reference to the solitary thyroid nodule. Acta Chir Scand. 1984;150:13–19
  239. Schaaf L, Pohl T, Schmidt R, Vardali I, Teuber J, Schlote-Sauter B, et al. Screening for thyroid disorders in a working population. Clin Invest. 1993;71:126–131
  240. Okamura K, Nakashima T, Ueda K, Inoue K, Omae T, Fujishima M. Thyroid disorders in the general population of Hisayama Japan, with special reference to prevalence and sex differences. Int J Epidemiol. 1987;16:545–549
  241. Rallison ML, Dobyns BM, Meikle AW, Bishop M, Lyon JL, Stevens W. Natural history of thyroid abnormalities: prevalence, incidence, and regression of thyroid diseases in adolescents and young adults. Am J Med. 1991;91:363–370
  242. Bjoro T, Holmen J, Kruger O, Midthjell K, Hunstad K, Schreiner T, et al. Prevalence of thyroid disease, thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected population. The Health Study of Nord-Trondelag (HUNT). Eur J Endocrinol. 2000;143:639–647
  243. Higuchi K, Nawata H, Maki T, Higashizima M, Kato K, Ibayashi H. Prolactin has a direct effect on adrenal androgen secretion. J Clin Endocrinol Metab. 1984;59:714–718
  244. Schiebinger RJ, Chrousos GP, Cutler GB, Loriaux DL. The effect of serum prolactin on plasma adrenal androgens and the production and metabolic clearance rate of dehydroepiandrosterone sulfate in normal and hyperprolactinemic subjects. J Clin Endocrinol Metab. 1986;62:202–209
  245. Carmina E, Rosato F, Maggiore M, Gagliano AM, Indovina D, Janni A. Prolactin secretion in polycystic ovary syndrome (PCO): correlation with the steroid pattern. Acta Endocrinol (Copenh). 1984;105:99–104
  246. Khandwala HM. Macroprolactinemia in a patient with infertility and hyperprolactinemia. South Med J. 2006;99:1282–1284
  247. Gibney J, Smith TP, McKenna TJ. The impact on clinical practice of routine screening for macroprolactin. J Clin Endocrinol Metab. 2005;90:3927–3932
  248. Derksen J, Nagesser SK, Meinders AE, Haak HR, van de Velde CJ. Identification of virilizing adrenal tumors in hirsute women. N Engl J Med. 1994;331:968–973
  249. Barbieri RL. Hyperandrogenic disorders. Clin Obstet Gynecol. 1990;33:640–654
  250. Zargar AH, Wani AI, Masoodi SR, Laway BA, Bashir MI, Salahuddin M. Epidemiologic and etiologic aspects of hirsutism in Kashmiri women in the Indian subcontinent. Fertil Steril. 2002;77:674–678
  251. Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med. 2003;349:776–788
  252. Moran C, Azziz R. 21-hydroxylase-deficient nonclassic adrenal hyperplasia: the great pretender. Semin Reprod Med. 2003;21:295–300
  253. Paula FJ, Gouveia LM, Paccola GM, Piccinato CE, Moreira AC, Foss MC. Androgen-related effects on peripheral glucose metabolism in women with congenital adrenal hyperplasia. Horm Metab Res. 1994;26:552–556
  254. Speiser PW, Serrat J, New MI, Gertner JM. Insulin insensitivity in adrenal hyperplasia due to nonclassical steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab. 1992;75:1421–1424
  255. Speiser PW, Knochenhauer ES, Dewailly D, Fruzzetti F, Marcondes JA, Azziz R. A multicenter study of women with nonclassical congenital adrenal hyperplasia: relationship between genotype and phenotype. Mol Genet Metab. 2000;71:527–534
  256. Bachega TA, Billerbeck AE, Marcondes JA, Madureira G, Arnhold IJ, Mendonca BB. Influence of different genotypes on 17-hydroxyprogesterone levels in patients with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin Endocrinol. 2000;52:601–607
  257. Deneux C, Tardy V, Dib A, Mornet E, Billaud L, Charron D, et al. Phenotype-genotype correlation in 56 women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2001;86:207–213
  258. Witchel SF, Lee PA. Identification of heterozygotic carriers of 21-hydroxylase deficiency: sensitivity of ACTH stimulation tests. Am J Med Genet. 1998;76:337–342
  259. Dewailly D, Vantyghem-Haudiquet MC, Sainsard C, Buvat J, Cappoen JP, Ardaens K, et al. Clinical and biological phenotypes in late-onset 21-hydroxylase deficiency. J Clin Endocrinol Metab. 1986;63:418–423
  260. Azziz R, Hincapie LA, Knochenhauer ES, Dewailly D, Fox L, Boots LR. Screening for 21-hydroxylase-deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study. Fertil Steril. 1999;72:915–925
  261. Siegel SF, Finegold DN, Lanes R, Lee PA. ACTH stimulation tests and plasma dehydroepiandrosterone sulfate levels in women with hirsutism. N Engl J Med. 1990;323:849–854
  262. Azziz R, Bradley EL, Potter HD, Boots LR. 3 beta-hydroxysteroid dehydrogenase deficiency in hyperandrogenism. Am J Obstet Gynecol. 1993;168:889–895
  263. Bongiovanni AM. Acquired adrenal hyperplasia: with special reference to 3 beta-hydroxysteroid dehydrogenase. Fertil Steril. 1981;35:599–608
  264. Pang SY, Lerner AJ, Stoner E, Levine LS, Oberfield SE, Engel I, et al. Late-onset adrenal steroid 3 beta-hydroxysteroid dehydrogenase deficiency. I. A cause of hirsutism in pubertal and postpubertal women. J Clin Endocrinol Metab. 1985;60:428–439
  265. Sakkal-Alkaddour H, Zhang L, Yang X, Chang YT, Kappy M, Slover RS, et al. Studies of 3 beta-hydroxysteroid dehydrogenase genes in infants and children manifesting premature pubarche and increased adrenocorticotropin-stimulated delta 5-steroid levels. J Clin Endocrinol Metab. 1996;81:3961–3965
  266. Lutfallah C, Wang W, Mason JI, Chang YT, Haider A, Rich B, et al. Newly proposed hormonal criteria via genotypic proof for type II 3beta-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab. 2002;87:2611–2622
  267. Joehrer K, Geley S, Strasser-Wozak EM, Azziz R, Wollmann HA, Schmitt K, et al. CYP11B1 mutations causing non-classic adrenal hyperplasia due to 11 beta-hydroxylase deficiency. Hum Mol Genet. 1997;6:1829–1834
  268. Azziz R, Dewailly D, Owerbach D. Clinical review 56: Nonclassic adrenal hyperplasia: current concepts. J Clin Endocrinol Metab. 1994;78:810–815
  269. Speiser PW, Dupont B, Rubinstein P, Piazza A, Kastelan A, New MI. High frequency of nonclassical steroid 21-hydroxylase deficiency. Am J Hum Genet. 1985;37:650–667
  270. Wilson RC, Nimkarn S, Dumic M, Obeid J, Azar M, Najmabadi H, et al. Ethnic-specific distribution of mutations in 716 patients with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Mol Genet Metab. 2007;90:414–421
  271. Gold EM. The Cushing syndromes: changing views of diagnosis and treatment. Ann Intern Med. 1979;90:829–844
  272. Ross EJ, Linch DC. Cushing's syndrome—killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet. 1982;2:646–649
  273. Urbanic RC, George JM. Cushing's disease—18 years' experience. Medicine (Baltimore). 1981;60:14–24
  274. Kaltsas GA, Korbonits M, Isidori AM, Webb JA, Trainer PJ, Monson JP, et al. How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome?. Clin Endocrinol (Oxf). 2000;53:493–500
  275. Orth DN. Cushing's syndrome. [erratum appears in N Engl J Med 1995 Jun 1;332(22):1527] N Engl J Med. 1995;332:791–803
  276. Putignano P, Bertolini M, Losa M, Cavagnini F. Screening for Cushing's syndrome in obese women with and without polycystic ovary syndrome. J Endocrinol Invest. 2003;26:539–544
  277. Kaltsas GA, Isidori AM, Kola BP, Skelly RH, Chew SL, Jenkins PJ, et al. The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women. J Clin Endocrinol Metab. 2003;88:2634–2643
  278. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2003;88:5593–5602
  279. Lado-Abeal J, Rodriguez-Arnao J, Newell-Price JD, Perry LA, Grossman AB, Besser GM, et al. Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgen levels. J Clin Endocrinol Metab. 1998;83:3083–3088
  280. Odagiri E, Yamanaka Y, Ishiwatari N, Jibiki K, Demura R, Demura H, et al. Studies on pituitary–gonadal function in patients with Cushing's syndrome. Endocrinol Jpn. 1988;35:421–427
  281. Findling JW, Raff H, Aron DC. The low-dose dexamethasone suppression test: a reevaluation in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2004;89:1222–1226
  282. Yaneva M, Mosnier-Pudar H, Dugue MA, Grabar S, Fulla Y, Bertagna X. Midnight salivary cortisol for the initial diagnosis of Cushing's syndrome of various causes. J Clin Endocrinol Metab. 2004;89:3345–3351
  283. Nakashima N, Young RH, Scully RE. Androgenic granulosa cell tumors of the ovary. A clinicopathologic analysis of 17 cases and review of the literature. Arch Pathol Lab Med. 1984;108:786–791
  284. Futterweit W, Scher J, Nunez AE, Strauss L, Rayfield EJ. A case of bilateral dermoid cysts, insulin resistance, and polycystic ovarian disease: association of ovarian tumors with polycystic ovaries with review of the literature. Mt Sinai J Med. 1983;50:251–255
  285. Gabrilove JL, Seman AT, Sabet R, Mitty HA, Nicolis GL. Virilizing adrenal adenoma with studies on the steroid content of the adrenal venous effluent and a review of the literature. Endocr Rev. 1981;2:462–470
  286. Freeman DA. Steroid hormone-producing tumors in man. Endocr Rev. 1986;7:204–220
  287. Meldrum DR, Abraham GE. Peripheral and ovarian venous concentrations of various steroid hormones in virilizing ovarian tumors. Obstet Gynecol. 1979;53:36–43
  288. Surrey ES, de Ziegler D, Gambone JC, Judd HL. Preoperative localization of androgen-secreting tumors: clinical, endocrinologic, and radiologic evaluation of ten patients. Am J Obstet Gynecol. 1988;158:1313–1322
  289. Waggoner W, Boots LR, Azziz R. Total testosterone and DHEAS levels as predictors of androgen-secreting neoplasms: a populational study. Gynecol Endocrinol. 1999;13:394–400
  290. Moller DE, Vidal-Puig A, Azziz R. Severe insulin-resistant hyperandrogenic syndromes. In:  Azziz R,  Nestler JE,  Dewailly D editor. Androgen excess disorders in women. Totowa, NJ: Humana Press; 2006;p. 129–138
  291. Barbieri RL, Ryan KJ. Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome: a common endocrinopathy with distinct pathophysiologic features. Am J Obstet Gynecol. 1983;147:90–101
  292. Vidal-Puig AJ, Moller DE. Inherited causes of androgen excess: classification, prevalence, clinical manifestations, and diagnosis. In:  Azziz R,  Nestler JE,  Dewailly D editor. Androgen excess disorders in women. Philadelphia, PA: Lippincott-Raven; 1997;p. 227–236
  293. Nagamani M, Van Dinh T, Kelver ME. Hyperinsulinemia in hyperthecosis of the ovaries. Am J Obst Gynecol. 1986;154:384–389
  294. Azziz R, Carmina E, Sawaya ME. Idiopathic hirsutism. Endocr Rev. 2000;21:347–362
  295. Gompel A, Wright F, Kuttenn F, Mauvais-Jarvis P. Contribution of plasma androstenedione to 5 alpha-androstanediol glucuronide in women with idiopathic hirsutism. J Clin Endocrinol Metab. 1986;62:441–444
  296. Unluhizarci K, Gokce C, Atmaca H, Bayram F, Kelestimur F. A detailed investigation of hirsutism in a Turkish population: idiopathic hyperandrogenemia as a perplexing issue. Exp Clin Endocrinol Diabetes. 2004;112:504–509
  297. Wild RA, Vesely S, Beebe L, Whitsett T, Owen W. Ferriman Gallwey self-scoring I: performance assessment in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:4112–4114
  298. Thessaloniki EA-SPCWG . Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod. 2008;23:462–477
  299. Hegele RA. Phenomics, lipodystrophy, and the metabolic syndrome. Trends Cardiovasc Med. 2004;14:133–137
  300. Oti M, Huynen MA, Brunner HG. Phenome connections. Trends Genet. 2008;24:103–106
  301. Azziz R. Diagnosing the diagnosis: why we must standardize the defining features of polycystic ovary syndrome. Ann Clin Biochem. 2008;45:3–5
  302. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab. 2007;92:405–413
  303. Dewailly D, Catteau-Jonard S, Reyss AC, Leroy M, Pigny P. Oligo-anovulation with Polycystic Ovaries (PCO) but not overt hyperandrogenism. J Clin Endocrinol Metab. 2006;91:3922–3927

 R.A. is a consultant for drug development at Proctor & Gamble. E.C. has nothing to disclose. D.D. has nothing to disclose. E.D.-K. has nothing to declare. H.F.E.-M. has nothing to disclose. W.F. has nothing to disclose. O.E.J. has nothing to disclose. R.S.L. is a consultant for Glaxo Smith Kline, Ferring, Quat. Rx, Organon, Serono, and Solvay. R.J.N. has nothing to disclose. A.E.T. is an employee of Novartis. S.F.W. has nothing to disclose.

PII: S0015-0282(08)01392-7

doi: 10.1016/j.fertnstert.2008.06.035

Fertility and Sterility
Volume 91, Issue 2 , Pages 456-488 , February 2009

Article Tools

* Image Usage & Resolution